Abstract
Introduction
The report provides a comprehensive financial and strategic analysis of the
mAb market, forecasting its commercial evolution out to 2014 and assessing
trends by product, company, therapy area, geography, technology and target
type. It also provides an insight into the direction of mAb technology
evolution and an analysis of pipeline dynamics.
Scope of this research
- Comprehensive financial strategic analysis of the mAb market out to 2014
- Global sales forecasts to 2014 for marketed and Phase III mAb products
- Analysis of market trends by product, company, geography, therapy area,
technology and target type
- Analysis of characteristics of key products and insight into direction of
mAb technology evolution and pipeline dynamics
Research and analysis highlights
The global prescription pharmaceutical market is expected to face a decline in
sales over 2012 to 2013 as a result of the ' patent cliff' . The patent cliff
will impact the small molecule market, in contrast, the mAb market segment
will continue to record robust growth.
Over the forecast period monoclonal antibodies are predicted to enjoy
double-digit growth while small molecule drugs face declining growth rates.
The main barrier to sales growth for small molecules, and particularly in the
US, is exposure to material generic competition, which Datamonitor believes
will have no effect on mAbs out to 2014.
This attractive growth rate and sales return potential has made mAb companies
a prime acquisition target in recent years, even during a period of economic
uncertainty, with a number of key acquisitions made during 2008-09.
Key reasons to purchase this research
- Assess the key products that will drive sales growth in the mAb market to
2014
- Identify the key geographic regions of the global mAb market and the
dynamics within these territories
- Understand the challenges and barriers to entry for new players seeking to
venture into the mAb market
| 
View Cart
